SEC 13F Intelligence

Fairfield, Bush & Co. / NVSN

Fairfield, Bush & Co.’s Novartis AG Position

Does Fairfield, Bush & Co. own Novartis AG (NVSN)? Yes — 19.3K shares worth $3M (+1.64% of its 13F portfolio) as of Q1 2026, down from 21.6K shares the prior filed quarter.

Position Value
$3M
Q1 2026
Shares
19.3K
% of Portfolio
+1.64%
Quarters Held
30
currently held

Position History NVSN

Reported value by quarter
Q4 ’18: $7MQ4 ’18Q1 ’19: $8MQ2 ’19: $6MQ3 ’19: $6MQ4 ’19: $6MQ4 ’19Q1 ’20: $5MQ2 ’20: $6MQ3 ’20: $6MQ4 ’20: $6MQ4 ’20Q1 ’21: $6MQ2 ’21: $6MQ3 ’21: $4MQ4 ’21: $4MQ4 ’21Q1 ’22: $4MQ2 ’22: $3MQ3 ’22: $3MQ4 ’22: $3MQ4 ’22Q1 ’23: $4MQ2 ’23: $4MQ3 ’23: $3MQ4 ’23: $3MQ4 ’23Q1 ’24: $3MQ2 ’24: $3MQ3 ’24: $3MQ4 ’24: $2MQ4 ’24Q1 ’25: $3MQ2 ’25: $3MQ3 ’25: $3MQ4 ’25: $3MQ4 ’25Q1 ’26: $3Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202619.3K$3M+1.64%
Q4 202521.6K$3M+1.57%
Q3 202522.9K$3M+1.50%
Q2 202524.2K$3M+1.66%
Q1 202525.1K$3M+1.77%
Q4 202425.5K$2M+1.46%
Q3 202424.9K$3M+1.71%
Q2 202428.6K$3M+1.83%
Q1 202428.8K$3M+1.65%
Q4 202329.4K$3M+1.74%
Q3 202333.3K$3M+2.22%
Q2 202340.8K$4M+1.13%
Q1 202341.2K$4M+1.34%
Q4 202233.8K$3M+2.02%
Q3 202234.0K$3M+1.83%
Q2 202237.1K$3M+1.85%
Q1 202241.6K$4M+1.83%
Q4 202141.6K$4M+1.74%
Q3 202153.1K$4M+1.41%
Q2 202161.9K$6M+1.53%
Q1 202165.0K$6M+1.59%
Q4 202065.6K$6M+1.81%
Q3 202065.6K$6M+1.82%
Q2 202065.7K$6M+2.05%
Q1 202065.7K$5M+2.25%
Q4 201967.4K$6M+2.35%
Q3 201968.1K$6M+2.05%
Q2 201971.1K$6M+2.21%
Q1 201978.2K$8M+2.49%
Q4 201879.1K$7M+2.34%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Fairfield, Bush & Co.’s full portfolio or all institutional holders of NVSN.